Inflammation and immune reaction, or pre-existing immunity towards commonly used viral vectors for gene therapy severely impair long-term gene expression in the central nervous system (CNS), impeding the possibility to repeat the therapeutic intervention. Here, we show that injection of a helper-dependent adenoviral (HD-Ad) vector by lumbar puncture into the cerebrospinal fluid (CSF) of non-human primates allows long-term (three months) infection of neuroepithelial cells, also in monkeys bearing a pre-existing anti-adenoviral immunity. Intrathecal injection of the HD-Ad vector was not associated with any sign of systemic or local toxicity, nor by signs of a CNS-specific immune reaction towards the HD-Ad vector. Injection of HD-Ad vectors into the CSF circulation may thus represent a valuable approach for CNS gene therapy allowing for long-term expression and re-administration.
Gene therapy holds promise as a beneficial drug delivery tool to the central nervous systems (CNS) in a number of pathological conditions, as recently shown in patients affected by Parkinson's disease. 1 Despite the classical work of Medawar, defining the brain as an immunoprivileged site, 2 the major hurdles affecting long-term transgene expression in the CNS are inflammation and immune responses directed against the viral vectors used for delivery. 3 Systemic as well as intra-parenchymal delivery of viral vectors usually induces humoral and cellular-mediated immune responses against the vectors and/or transgene products, leading to inflammation, short-term persistence of gene expression and the elimination of transduced cells, [4] [5] [6] limiting also the possibility of repeated administration. Adenoviral (Ad) vectors for gene therapy have the additional concern that neutralizing antibodies to adenovirus serotype 5, the one used for most Ad gene therapy vectors, are detected in the majority of the human population. 7 Ad vectors have evolved from first generation to helper-dependent (HD) Ad vectors, devoid of most viral genes and characterized by reduced immunogenicity, as tested also in the brain. 6, 8 We and others have previously shown that injection of viral vectors into the cisterna magna, or through lumbar puncture, might represent an efficient CNS delivery system in both small (mice) and large (non-human primates) animals. [9] [10] [11] [12] [13] Vector administration into the cerebrospinal fluid (CSF) circulation, while bypassing the blood-brain barrier, allows viral vector-transduction of neuroepithelial cells and the delivery of transgene products to the whole CNS through the ventricular circulation. Inflammatory and immune responses towards HD-Ad vectors injected through this route have not been investigated so far. We have injected, by lumbar puncture, murine IL-4 producing HD-Ad vector in monkeys with or without pre-existing anti-Ad immunity to study HD-Ad vector persistence, immunogenicity and toxicity.
Vector construction and production
The helper-dependent Ad vector was generated in the context of the STK-120 vector backbone:
14 the Ad-G/IL-4 vector carried the expression cassettes for murine IL-4 and the green fluorescent protein (GFP) cDNAs, respectively driven by the phosphoglycerokinase (PGK) and the cytomegalovirus (CMV) immediate-early promoter. A formal proof of murine IL-4 inactivity in a primate environment is lacking, however, there is a formal proof of the lack of cross-reactivity between murine and human IL-4. 15 Human and Rhesus IL-4 share high homology (Identities ¼ 140/153 (91%), Positives ¼ 147/ 153 (96%), Gaps ¼ 0/153 (0%)), while between murine and Rhesus IL-4, there is low homology (Identities ¼ 61/ 149 (40%), Positives ¼ 86/149 (57%), Gaps ¼ 9/149 (6%)). Finally, the IL-4 residues crucial for the receptor binding are aa80-86 and are not among the conserved residues. 16 All this considered, it appears highly unlikely that murine IL-4 is able to exert immunosuppressive activity in a non-human primate environment. Viral stocks were obtained and titrated as previously described.
17
The Ad-G/IL-4 vector transduces neuroepithelial cells of non-human primates upon administration through lumbar puncture Table 1 ). The biodistribution of viral vectors outside the CNS after lumbar puncture administration was examined at sacrifice by immunohistochemistry and real-time PCR. Expression of GFP was detected in all monkeys in the ependyma of the spinal cord and cauda equina, independently from the presence of pre-existing antiAd immunity (Figures 1a and b) . Viral genomes were detected using two independent pairs of primers, targeting the stuffer-cosmid DNA and the murine IL-4 expressing cassette, in the spinal cord of all monkeys up to the cervical level (Figure 1c ), but were not found in the brain (data not shown). Quantitative real-time PCRperformed in a number of tissues and organs from all animals, including cervical lymph nodes, liver, lung, spleen, kidney, gut, skeletal muscle and testis-did not show any viral vector DNA signal outside the CNS (data not shown). Transgene expression was also measured. Vector-derived, murine IL-4 was detected (2-14 pg ml À1 ) by fluorescent ELISA in the CSF of all four monkeys even 2-3 months after injection (Figure 1d ), regardless of anti-Ad pre-immunization.
Intrathecal administration of Ad-G/IL-4 vector is neither toxic nor immunogenic in non-human primates
To analyze any sign of local or systemic toxicity in Ad-G/IL-4-injected monkeys, we analyzed a number of hematological parameters at regular intervals during the three-months post-injection period in all monkeys as well as the CNS tissue morphology at the time of killing. No alterations were detected in the hematocrit, white and red blood cell count, and blood levels of urea, creatinin, alkaline phosphatase, GPT, albumin, bilirubin, hemoglobin and total proteins throughout the follow-up, with the exception of monkey no. 3, which showed a transient increase in WBC count (17.3 Â 10 9 /l) one week after injection, possibly as a reaction to the injection procedure ( Table 2) . No sign of tissue toxicity, and particularly no damage to myelin and axons and no infiltration of inflammatory cells were detected in the areas adjacent to transduced ependymal cells ( Figure 2 ). No obvious behavioral change was noted in the injected primates.
To analyze the immune response to the injected vector, we serially measured albumin content, immunoglobulin Blood-brain barrier permeability was evaluated in CSF samples according to Thompson's criteria, intrathecal IgG synthesis using the IgG index, and Anti-adenovirus antibody titer in blood and CSF was tested with a neutralization assay, as previously described. HD-Ad vectors injected into the CSF are not immunogenic E Butti et al content and anti-Ad antibodies in sera and CSF from all treated monkeys. Pre-immunized animals had serum neutralizing anti-Ad antibody titers comparable to adeno-infected human patients (1/200-1/400) throughout the follow-up, while non-pre-immunized monkeys seroconverted at low titers (o1/10) one month after intrathecal injection of Ad-G/IL-4 (Table 1) . Notably, naive macaques were negative for anti-Ad antibodies in the CSF throughout the study, while pre-immunized animals showed very low CSF anti-Ad antibody titers, compatible with passive transfer from the serum (Table  1) . No alterations in the albumin ratio, as a measure of blood-brain barrier integrity, nor of the immunoglobulin ratio (Link's index), as a marker of intrathecal Ig synthesis were detected in the four animals with the exception of a single, blood-contaminated CSF sample (Table 1) . No oligoclonal band patterns typical of intrathecal synthesis of immunoglobulins were detected in the paired serum and CSF samples from macaques injected with Ad-G/IL-4, with the exception of monkey no. 2, which, however, displayed the same pattern also before the vector administration (Figure 3a) . Despite the lack of data in large series, the occurrence of oligoclonal bands is more frequent in healthy primates than in healthy humans. 18 Finally, peripheral blood mononuclear cells (PBMCs) from pre-immunized monkeys proliferated at significant levels when challenged with heatinactivated, sonicated, adenoviral particles, as opposed to PBMCs from non-pre-immunized macaques, which showed no proliferative response up to three months after vector injection (Figure 3b ). These data indicate that intrathecal administration of a HD-Ad vector in nonhuman primates is safe since it does not induce any PBMC proliferation against Ad antigens.
A major limitation of in vivo human gene therapy is the immunogenicity of viral vectors, which prevents their use in chronic diseases where prolonged expression or repeated injections of the therapeutic vectors are required. 3 A possible exception is represented by immune-privileged areas, such as the subretinal space or the CSF, where vector-induced inflammatory or immunogenic responses may be significantly less pronounced. 2 We have previously shown that intrathecal delivery of an immunogenic HSV-1-derived vector in mice and macaques results only occasionally in a mild inflammatory reaction, resolving in one week.
12, 19 The Minneapolis, MN, USA) . The resulting signals were amplified with 10-acethyl-3,7-dihydroxyphenazine (Molecular Probes Inc., Eugene, OR, USA), read on Victor3 Perkin-Elmer, detection limit E1 pg ml À1 . Abbreviations: Alk. Phosph, alkaline phosphatase; GPT, glutamate pyruvate transaminase; GT, gene therapy; Hb, hemoglobin; Hct, hematocrit; RBC, red blood cells; Tot. Prot, total protein content; WBC, white blood cells. Blood samples were collected from treated monkeys and evaluated for hematology (complete blood cell count; hemoglobin; hematocrit; mean corpuscular volume (MCV), reticulocytes, iron) and clinical chemistry (including Na, Cl, HCO 3 , Ca, K, P electrolytes, C-reactive protein, total proteins, albumin, kidney function (urea, creatinine, uric acid), liver/heart function (g-glutamyltransferase (gGT), serum glutamic-oxaloacetic transaminase (SGOT)], serum glutamic-pyruvic transaminase (SGPT), total bilirubin, alkaline phosphatase), cholesterol and glucose.
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E Butti et al use of first-generation HSV-1 vectors is hampered, however, by their short-term expression and these vectors are thus unsuitable for chronic diseases such as multiple sclerosis. On the other hand, first-generation Ad vectors, which express transgenes as well as viral genes for prolonged periods, cause inflammation and anti-Ad immunity when delivered intraventricularly. 5 We now provide evidence that injection of a HD-Ad vector devoid of all viral genes into the CSF of monkeys results in the transduction of neuroepithelial cells and long-term transgene expression in the absence of inflammatory or immune responses. Spreading of the Hd-Ad vector genomes and IL-4 was limited to the CSF and the CNS tissue in all monkeys. We also show that intrathecal injection of HD-Ad in macaques bearing high levels of circulating neutralizing anti-adenovirus antibodies is feasible and safe, and does not induce tissue toxicity or inflammation. In naive macaques, the same procedure induces only seroconversion at negligible levels, but no adenovirus-specific T-cell-mediated immune response. The late appearance of an immune reaction, absent in the first three months, is highly unlikely. Thus, repetition of the intrathecal administration of the viral vector is conceivable, when transgene expression may fade out, to maintain the therapeutic efficacy in a clinical setting. The administration of HD-Ad by lumbar puncture may, therefore, represent a reasonable way to deliver, through the CSF circulation, therapeutic macromolecules to the CNS for significant periods also in human patients. No oligoclonal bands appear specifically in the CSF of injected monkeys after treatment. Monkey no. 2 displays CSF-specific oligoclonal bands (arrows) present before Ad vector injection. CSF-oligoclonal bands were evaluated by isoelectric focusing followed by Western blot and immunofixation with biotin-labeled rabbit anti-human IgG as previously described. 20 (b) Ad-specific T-cell reactivity in macaques injected with Ad-G/IL-4. HD Ad vectors injected, three months before, into the CSF of macaques by lumbar puncture do not induce T-cell reactivity as measured by 3 H-labeledthymidine incorporation using Ad particles disrupted by sonication as stimulating ag. A weak, but consistent, proliferative response was elicited only in pre-immunized monkeys. The assay shown is representative of three independent experiments, and average SI7s.e.m. is displayed. For T-cell proliferation assays in macaques, purified blood-mononuclear cells were cultured in 96-well culture plates (Costar, Cambridge, MA, USA) in RPMI 1640 medium (Sigma, St Louis, MO, USA) supplemented with 5% FCS (Mascia Brunelli, Milan, Italy), 2 mM l-glutamine, penicillin G (100 U ml À1 ) and streptomycin (100 mg/ml) (GIBCO-BRL, Life Technologies, Paisley, UK), and containing adenoviral protein. Cultures were incubated in triplicate for 3 days in 5% CO 2 in air, and then pulsed for 18 h with 0.5 mCi per well of [ 
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